FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels

Acute myeloid leukaemia (AML) is a fatal disease for most patients. We have found that ferumoxytol (Feraheme®), a FDA approved iron oxide nanoparticle for iron deficiency treatment, demonstrates an anti-leukaemia effect in vitro and in vivo. Using leukaemia cell lines and primary AML patient samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Trujillo-Alonso, Vicenta, Pratt, Edwin C., Zong, Hongliang, Lara-Martinez, Andres, Kaittanis, Charalambos, Rabie, Mohamed O., Longo, Valerie, Becker, Michael W., Roboz, Gail J., Grimm, Jan, Guzman, Monica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554053/
https://www.ncbi.nlm.nih.gov/pubmed/30911166
http://dx.doi.org/10.1038/s41565-019-0406-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554053/
https://www.ncbi.nlm.nih.gov/pubmed/30911166
http://dx.doi.org/10.1038/s41565-019-0406-1

Ejemplares similares